Qualigen Therapeutics, Inc. (QLGN)
Qualigen Therapeutics, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Carlsbad, CA, US. The stock last traded at $3.21, up 5.59% on the session, giving a market capitalisation of $5.4M. On trailing twelve-month figures it carries a trailing P/E of -0.51, a net margin of 0.0%. Its beta of 0.28 implies it has historically moved less than the broad market.
Qualigen Therapeutics, Inc. is a biotechnology enterprise focused on advancing groundbreaking treatments for both cancer and infectious diseases. In addition to its developmental pipeline, the company offers FastPack, an efficient system designed for swift diagnostic testing. Its therapeutic candidates currently undergoing development include QN-302, an investigational compound targeting pancreatic ductal adenocarcinoma; QN-247, a DNA-coated gold nanoparticle formulated to combat various types of cancer; and RAS-F, a small-molecule inhibitor designed to block RAS oncogene protein-protein interactions, thereby impeding RAS mutations and suppressing tumor growth. The company is also progressing with the STARS blood cleansing system, an innovative DNA/RNA-based device engineered to purify a patient's bloodstream by eliminating tumor-derived substances and viruses. Founded in 1996, Qualigen Therapeutics, Inc. is headquartered in Carlsbad, California.
Qualigen Therapeutics, Inc. is most often compared with the following Healthcare names: